Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(1)
1 unique interventions1 categories

Analytics

Trial Phases

Phase 21

Trial Status

Recruiting1

Role Distribution

Other Roles1

Activity Timeline

Clinical Trials (1)

NCT07447817Phase 2Recruiting
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Studychair

Research Network

Collaboration Network

21 collaborators·21 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

John Mascarenhas, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
16 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

John MascarenhasKaryopharm Therapeutics Inc+2 more
Collaborated on 1 trial
Similarity Score34%

Abdulraheem Yacoub, MD

University of Kansas School of Medicine

Moderately Similar
1 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

John MascarenhasKaryopharm Therapeutics Inc+2 more
Collaborated on 1 trial
Similarity Score34%

Ronald Hoffman, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
10 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

John MascarenhasNational Cancer Institute (NCI)
Similarity Score30%

Martha Wadleigh, MD

Dana-Farber Cancer Institute

Moderately Similar
3 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Ayalew Tefferi, MD

Mayo Clinic

Moderately Similar
4 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score30%

Will Savage, MD PhD

Disc Medicine

Related
6 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Similarity Score20%

Claudio G. Brunstein, MD, PhD

Masonic Cancer Center, University of Minnesota

Related
7 trials

Shared therapeutic areas:

Primary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Primary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Primary Myelofibrosis

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score10%

Yifan Zhai, MD, PhD

Ascentage Pharma Group Inc.

Related
14 trials

Shared therapeutic areas:

Primary Myelofibrosis
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT07447817Phase 2StudyChair

Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
Recruiting

All 1 trials loaded